<DOC>
	<DOCNO>NCT01191541</DOCNO>
	<brief_summary>Several group , especially PETHEMA group ( LPA96 99 trial ) , obtain low relapse rate newly diagnose Acute Promyelocytic Leukemia ( APL ) patient combine ll-transretinoic acid ( ATRA ) anthracyclines without Ara-C , suggest avoid Ara-C chemotherapy APL reduce treatment toxicity without increase relapse . While relapse rate child white blood cell ( WBC ) count great 10×109/L presentation high WBC count less 10×109/L ( 31 % 3.5 % , respectively ) LPA96 99 trial . A recent adult randomize trial show avoid Ara-C lead increase risk relapse APL patient WBC count less 10×109/L . The role Ara-C remain controversial . And limited data report child APL far .</brief_summary>
	<brief_title>Cytarabine ( Ara-C ) Children With Acute Promyelocytic Leukemia ( APL )</brief_title>
	<detailed_description>Some study suggest patient high-risk disease treat intensified dos anthracycline , intermediate/ high-dose Ara-C As2O3 early consolidation , decrease risk relapse.However , high cumulative dose anthracycline may lead cardiac toxicity , especially child . In addition , contain Ara-C lead therapy-related toxicity . The benefit add Ara-C schedule questionable remains matter investigation child .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<criteria>Acute Promyelocytic Leukemia ( APL ) &gt; 16</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>ara-c</keyword>
	<keyword>As2O3</keyword>
	<keyword>pediatric</keyword>
	<keyword>acute</keyword>
</DOC>